Moderna, a biotech giant that gained prominence during the COVID-19 pandemic, has revolutionized the biotechnology domain.

Urge your representatives in Congress to support its programs to increase access to vaccines around the world.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Shares of Moderna Inc. MRNA inched 0.55% higher to $53.09 Friday, on what proved to be an all-around mixed trading session ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

The 2024-2025 COVID-19 vaccines are available, and the CDC recommends that adults over 65 and immunocompromised people get ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

Last week I saw a somewhat shabbily dressed man in the pharmacy trying to get a Covid booster. They told him it would cost $130. (It was the Moderna ...

This content was published on Oct 26, 2024 The Swiss Federal Democratic Union (EDU) has handed in referendum signatures to seek a vote to prevent the Eurovision Song Contest (ESC) from taking ...

Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers ...

UBS lowered the firm’s price target on Moderna (MRNA) to $108 from $140 and keeps a Buy rating on the shares following a model review.

Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers’ 2024 Top Employers Survey for the tenth consecutive ...